A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
Trial details
- Registry ID
- NCT06022224
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIALNCT06022224 | IBRX | Phase 2, Phase 3 | Terminated | 2022-06-23Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |